Postoperative Hyperbaric Oxygen Treatments to Reduce Complications in Diabetic Patients Undergoing Vascular Surgery

Diabetes Clinical Trial

— HODiVA  

Official title:

Postoperative Hyperbaric Oxygen Treatments to Reduce Complications in Diabetic Patients Undergoing Vascular Surgery (HODiVA) - A Double Blind, Randomized Controlled Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01002209
• Other study ID #: HODIVA
• Status: Withdrawn
• Phase: Phase 2/Phase 3
• Start date: October 2019
• Est. completion date: October 2020

Study information

• Verified date: November 2020
• Source: Karolinska Institutet
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial aims to evaluate if hyperbaric oxygen treatment (HBO) given postoperatively is effective in reducing healing time and wound complications after lower extremity bypass surgery in patients with diabetes.

Hypothesis: Postoperative HBO treatment is effective in reducing complications in patients with diabetes undergoing peripheral vascular surgery

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 2020
• Est. primary completion date: October 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients are eligible for inclusion if the following criteria are fulfilled

• Informed consent obtained

• Scheduled for lower extremity open vascular surgery

• Diabetes treated with insulin or oral antidiabetic medicine

• Age = 18 years

Exclusion Criteria:

• Contraindications to HBO therapy

• Pregnancy (women of childbearing potential will undergo pregnancy test before inclusion)

• Patients already in HBO treatment

• Vascular reoperation

• Creatinine > 250 mmol/L

• NYHA class IV heart failure or severe cardiopulmonary disease with desaturation judged to be incompatible with safe HBO/ placebo therapy in a monoplace chamber

• Clinically significant chronic obstructive pulmonary disease.

• Acute sepsis.

• Malignancy or other serious medical condition where it is likely that the patient will significantly deteriorate or not survive within the two years of follow up.

• Simultaneous or previous (within 30 days prior to study entry participation in a clinical study using experimental drugs or devices.

• Mental condition making the subject unable to understand the concepts and risk of the study

Related Conditions & MeSH terms

• Arterial Occlusive Disease
• Arterial Occlusive Diseases
• Diabetes
• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Intervention

Procedure:
• Hyperbaric Oxygen treatment (HBO)
HBO treatment will be given in a monoplace chamber and will start on first postoperative day (study day 1). The HBO group will be treated with 100% oxygen at 2.5 bar for 100 min with two 10 min airbrakes (without mask). HBO treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO/placebo treatment and who have a clearly uncomplicated postoperative course will terminate HBO/placebo treatment on the day of discharge from hospital.
• Sham HBO
HBO sham treatment will start on first postoperative day (study day 1). HBO sham treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO sham treatments and who have a clearly uncomplicated postoperative course will terminate HBO sham treatment on the day of discharge from hospital. For patient blinding purposes, the sham group will breathe air and will be given a brief compression to 1.5 bar at the beginning of each treatment after which the chamber is slowly decompressed to 1.1, 1.2 , 1.3, or 1.4 bar corresponding to 0.23 ,0.25, 0.27, and 0.29 bar inspired oxygen. Two 10 min "airbrakes" will also be included.

Locations

Country	Name	City	State
Sweden	Karolinska University Hospital	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
Karolinska Institutet

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to complete healing of operative wounds		7-365 days
Secondary	Number of wound infections at 7 days assessed by ASEPSIS score. A score over 20 will be considered as a wound infection.		7 days (plus minus 3 days)
Secondary	Number of wound infections at 30 days assessed by ASEPSIS score. A score over 20 will be considered as a wound infection.		30 days (plus minus 3 days)
Secondary	The severity of wound infection defined as by ASEPSIS score: 0-10= satisfactory healing 11-20= disturbed healing 21-30= minor wound infection 31-40= moderate wound infection >40= severe wound infection.		highest score up to 30 days (plus minus 3 days)
Secondary	A combination of any wound infection and/or unhealed wounds at 30 days (combined endpoint).		30 days (plus minus 3 days)
Secondary	SF-36 score		7, 14, 28, 365 days (plus minus 3 days)
Secondary	Major amputation or death. This will be assessed as "amputation-free survival". A major amputation is defined as any ipsilateral amputation through or above the ankle.		0-365 days
Secondary	Tissue perfusion and oxygenation on dorsum of foot on operated extremity as assessed by Transcutaneous oximetry during normobaric air breathing and after 6 min normobaric 100% oxygen challenge		day 3-5, 7 and 14, 28, 365 (plus minus 3 days)
Secondary	HBO complications (confinement anxiety, barotrauma, oxygen convulsions)		During HBO treatment up to day 6